Health Care Equipment & Services

Veeva’s Q4 earnings beat forecasts, powered by AI‑enhanced CRM and high‑margin life‑science cloud services, but analysts weigh valuation premiums against AI risks and market tightening.

ResMed’s robust asset backing, FDA‑approved sleep‑disorder tech, and transparent insider moves boost investor confidence amid growing pediatric sleep‑health demand.

Solventum Corp’s steady $48.20 stock reflects solid mid‑cap value: low P/E, strong cash flow, and 93% client retention, all powered by AI‑driven population‑health analytics.

Labcorp’s rising stock reflects analyst optimism, but sustaining gains demands tight cost control, AI‑driven diagnostics, and patient‑centric service models.

Veeva Systems beats Q4 earnings, touts AI‑driven CRM growth, and aims for $6B revenue by 2030 amid regulatory and competitive challenges.

Coloplast names Gavin Wood, a Johnson & Johnson veteran, as CEO – a strategic move to boost product pipeline, market reach and operational efficiency in medical technology.

Demant’s March 5 AGM shows no new moves, keeping its Danish C25 role steady—short‑sellers see limited upside, yet the company remains a stable investment choice.

Straumann Holding AG’s March 2026 share price reflects a muted Swiss market; solid revenue growth, hybrid‑manufacturing prospects and AI‑driven implant tech drive a cautious investment outlook amid regulatory and competitive pressures.

Boston Scientific Corp. shows steady growth and strong innovation in minimally invasive cardiology and electrophysiology, positioning it for continued upward market performance.

Cooper Companies Q1 2026 shows stronger earnings, 5 % revenue lift, 14 % EPS growth, and new Vision‑Plus lenses with FDA/CE clearance, boosting health‑tech innovation and patient outcomes.